Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

iwMyeloma 2022 | Therapeutic approaches for AL amyloidosis

Angela Dispenzieri • 27 Mar 2022

iwMyeloma 2022

Amyloidosis Bortezomib Cyclophosphamide Daratumumab Dexamethasone

ANDROMEDA

Angela Dispenzieri, MD, Mayo Clinic, Rochester, MN, briefly discusses therapeutic approaches and the importance of clinical trials in the treatment of amyloidosis. Dr Dispenzieri highlights the standard of care for patients with light chain (AL) amyloidosis, and further discusses the ANDROMEDA trial (NCT03201965) evaluating the use of subcutaneous daratumumab plus bortezomib, cyclophosphamide and dexamethasone (Dara-VCd) versus VCd alone for the treatment of AL amyloidosis. To conclude, Dr Dispenzieri highlights the unmet need in therapeutic options for patients with stage IIIb disease. This interview took place at The International Workshop on Myeloma 2022, held in Scottsdale, AZ.

Unmet needs in amyloidosis: early diagnosis, treating relapsed disease & progression criteria

Angela Dispenzieri • 6 Sep 2023

Emerging AL amyloidosis treatments: immunotherapies & targeting amyloid plaque deposits

Angela Dispenzieri • 6 Sep 2023

The current SOC in AL amyloidosis: dara-CyBorD & considerations for patients with relapsed disease

Angela Dispenzieri • 6 Sep 2023

Rationale behind the watch and wait strategy in smoldering myeloma

Angela Dispenzieri • 6 Sep 2023

Related Videos

Safety and efficacy of NXC-201, an anti-BCMA CAR-T, in R/R AL amyloidosis

Vaishali Sanchorawala • 11 Dec 2023

Quantifying biomarkers on lambda amyloidogenic light chains to diagnose AL amyloidosis

Vaishali Sanchorawala • 11 Dec 2023

The impact of amyloid deposits in AL amyloidosis

Paolo Milani • 22 Nov 2023

Safety of birtamimab in AL amyloidosis: pooled analysis from multiple studies

Vaishali Sanchorawala • 12 Dec 2023